Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

NCT03403205 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

214

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate the program

Conditions

Wilson Disease

Interventions

DRUG: ALXN1840
DRUG: SoC Therapy

Sponsor

Alexion Pharmaceuticals, Inc.